Table 2.
Acute-phase trials for ziprasidone.
| Authors | Zipr. dose (mg/day) | Comparator | n | Duration | Efficacy of ziprasidone |
|---|---|---|---|---|---|
| Keck et al18 | 40 and 120 | Placebo | 139 | 4 w. | 120 mg superior overall |
| Daniel et al19 | 80 and 120 | Placebo | 302 | 6 w. | Both dose superior overall, positive and negative |
| Goff et al24 | 4, 10, 40, and 160 | Haloperidol (15 mg) | 90 | 4 w. | 160 mg equal |
| Addington et al20 | 80–160 | Risperidone (3 to 5 mg) | 296 | 8 w. | Equal |
| Simpson et al21 | 40, 60 and 80 | Olanzapine (5, 10 or 15 mg) | 269 | 6 w. | Equally effective |
| Zimbroff et al22 | 80–120–160 | Aripiprazolo (10–15–30 mg) | 253 | 4 w. | Both treatments were effective |
| Grootens et al29 | 80–120–160 | Olanzapine (10–15–20 mg) | 73 | 8 w. | Comparable reductions from baseline in the primary outcome variable PANSS total |
| Kahn et al25 | 40–160 | Haloperidol (1–4 mg/day) | 489 | 48 w. | Lower risks for any cause Discontinuation |